These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

500 related articles for article (PubMed ID: 35897648)

  • 1. Targeting VIP and PACAP Receptor Signaling: New Insights into Designing Drugs for the PACAP Subfamily of Receptors.
    Lu J; Piper SJ; Zhao P; Miller LJ; Wootten D; Sexton PM
    Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A cloned frog vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating polypeptide receptor exhibits pharmacological and tissue distribution characteristics of both VPAC1 and VPAC2 receptors in mammals.
    Alexandre D; Anouar Y; Jegou S; Fournier A; Vaudry H
    Endocrinology; 1999 Mar; 140(3):1285-93. PubMed ID: 10067855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression localisation and functional activity of pituitary adenylate cyclase-activating polypeptide, vasoactive intestinal polypeptide and their receptors in mouse ovary.
    Barberi M; Muciaccia B; Morelli MB; Stefanini M; Cecconi S; Canipari R
    Reproduction; 2007 Aug; 134(2):281-92. PubMed ID: 17660238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Backup Mechanisms Maintain PACAP/VIP-Induced Arterial Relaxations in Pituitary Adenylate Cyclase-Activating Polypeptide-Deficient Mice.
    Ivic I; Fulop BD; Juhasz T; Reglodi D; Toth G; Hashimoto H; Tamas A; Koller A
    J Vasc Res; 2017; 54(3):180-192. PubMed ID: 28490016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug Repositioning For Allosteric Modulation of VIP and PACAP Receptors.
    Langer I; Latek D
    Front Endocrinol (Lausanne); 2021; 12():711906. PubMed ID: 34867774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization and expression of different pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide receptors in rat ovarian follicles.
    Vaccari S; Latini S; Barberi M; Teti A; Stefanini M; Canipari R
    J Endocrinol; 2006 Oct; 191(1):287-99. PubMed ID: 17065411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pituitary adenylate cyclase-activating polypeptide receptors mediating insulin secretion in rodent pancreatic islets are coupled to adenylate cyclase but not to PLC.
    Jamen F; Puech R; Bockaert J; Brabet P; Bertrand G
    Endocrinology; 2002 Apr; 143(4):1253-9. PubMed ID: 11897681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pituitary adenylate cyclase activating polypeptide: an important vascular regulator in human skin in vivo.
    Seeliger S; Buddenkotte J; Schmidt-Choudhury A; Rosignoli C; Shpacovitch V; von Arnim U; Metze D; Rukwied R; Schmelz M; Paus R; Voegel JJ; Schmidt WE; Steinhoff M
    Am J Pathol; 2010 Nov; 177(5):2563-75. PubMed ID: 20889562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pituitary adenylate cyclase-activating polypeptide promotes eccrine gland sweat secretion.
    Sasaki S; Watanabe J; Ohtaki H; Matsumoto M; Murai N; Nakamachi T; Hannibal J; Fahrenkrug J; Hashimoto H; Watanabe H; Sueki H; Honda K; Miyazaki A; Shioda S
    Br J Dermatol; 2017 Feb; 176(2):413-422. PubMed ID: 27453364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardioprotective role of the VIP signaling system.
    Dvoráková MC
    Timely Top Med Cardiovasc Dis; 2005 Oct; 9():E33. PubMed ID: 16341283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. VPAC2-R mediates the lipolytic effects of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide in primary rat adipocytes.
    Akesson L; Ahrén B; Edgren G; Degerman E
    Endocrinology; 2005 Feb; 146(2):744-50. PubMed ID: 15514088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Physiological significance of pituitary adenylate cyclase-activating polypeptide (PACAP) in the nervous system].
    Hashimoto H
    Yakugaku Zasshi; 2002 Dec; 122(12):1109-21. PubMed ID: 12510388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Understanding VPAC receptor family peptide binding and selectivity.
    Piper SJ; Deganutti G; Lu J; Zhao P; Liang YL; Lu Y; Fletcher MM; Hossain MA; Christopoulos A; Reynolds CA; Danev R; Sexton PM; Wootten D
    Nat Commun; 2022 Nov; 13(1):7013. PubMed ID: 36385145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vasoactive intestinal polypeptide and pituitary adenylate cyclase-activating polypeptide receptor chimeras reveal domains that determine specificity of vasoactive intestinal polypeptide binding and activation.
    Hashimoto H; Ogawa N; Hagihara N; Yamamoto K; Imanishi K; Nogi H; Nishino A; Fujita T; Matsuda T; Nagata S; Baba A
    Mol Pharmacol; 1997 Jul; 52(1):128-35. PubMed ID: 9224822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions.
    Vaudry D; Gonzalez BJ; Basille M; Yon L; Fournier A; Vaudry H
    Pharmacol Rev; 2000 Jun; 52(2):269-324. PubMed ID: 10835102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vasoactive intestinal peptide/pituitary adenylate cyclase activating polypeptide, and their receptors and cancer.
    Moody TW; Nuche-Berenguer B; Jensen RT
    Curr Opin Endocrinol Diabetes Obes; 2016 Feb; 23(1):38-47. PubMed ID: 26702849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptors in human benign hyperplastic prostate.
    Solano RM; Carmena MJ; Carrero I; Cavallaro S; Roman F; Hueso C; Travali S; Lopez-Fraile N; Guijarro LG; Prieto JC
    Endocrinology; 1996 Jul; 137(7):2815-22. PubMed ID: 8770902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of mRNAs for PACAP and its receptor in human neuroblastomas and their relationship to catecholamine synthesis.
    Isobe K; Kaneko M; Kaneko S; Nissato S; Nanmoku T; Takekoshi K; Okuda Y; Kawakami Y
    Regul Pept; 2004 Dec; 123(1-3):29-32. PubMed ID: 15518890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification and functional properties of the pituitary adenylate cyclase activating peptide (PAC1) receptor in human benign hyperplastic prostate.
    Solano RM; Carmena MJ; Busto R; Sánchez-Chapado M; Guijarro LG; Prieto JC
    Cell Signal; 1999 Nov; 11(11):813-9. PubMed ID: 10617284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Perspectives on pituitary adenylate cyclase activating polypeptide (PACAP) in the neuroendocrine, endocrine, and nervous systems.
    Arimura A
    Jpn J Physiol; 1998 Oct; 48(5):301-31. PubMed ID: 9852340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.